Revisiting What Might Save Life of Cancer Patients Actually

Bahram Alamdary Badlou

Research and Development Department, Zeist, The Netherlands

Dr. Bahram Alamdary Badlou, Research and Development Department, Zeist, The Netherlands.

Keywords: Cancer; Immune Thrombocytopenia; Myelofibrosis

Abstract

Cancer patients 5-years survival chance (5YSC) is still after a Century research and development (R&D)do not changed significantly, as infectious diseases did. How Medici might increase 5YSC is not elucidated yet.
Recently I introduced death triangle machinery (DTM), which might play pivotal role in accelerating 5YSC toward increased morbidity and mortality rate in the last years [1].
Immune thrombocytopenia (ITP) is a common bleeding disorder caused primarily by auto-antibodies against platelet GPIIbIIIa and/or the GPIb-receptor complex.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).